HomeAbout PERSConduct DisorderThe PERS studyPatients and relativesResources
Members
About PERS Members CIBERSAM

CIBERSAM

Logo

CIBERSAM
Hospital General Universitario Gregorio Marañón | Pabellón de Gobierno 1st floor
Doctor Esquerdo 46
28007 Madrid (España)

Homepage

Project leader

Dr. Celso Arango López

Dr. Celso Arango López

Phone: +34-915570795
Fax: +34-915570812
Email

Project staff

Dr. Mara Parellada Redondo

Phone: +34-915868133
Fax: +34-914265004
Email

Dr. Dolores Moreno Pardillo

Phone: +34-915868133
Fax: +34-914265004
Email

Dr. Carmen Moreno Ruiz

Phone: +34-915868133
Fax: +34-914265004
Email

Dr. Laura Pina Camacho

Phone: +34-915864006
Fax: +34-914265004
Email

Dr. Petra Sánchez Mascaraque

Phone: +34-915864006
Fax: +34-914265004
Email

Group

Institute presentation

Description of organisation

Gregorio Marañón General Hospital (HGUGM) is the largest university hospital in Spain (www.hggm.es). The Department of Psychiatry and its Adolescent Unit, headed by Dr. Celso Arango, have extensive experience conducting both private and non-profit clinical trials in schizophrenia and other psychoses (www.hggm.es/ua). HGUGM is the co-ordinating centre for the Spanish Psychiatric Research Network (CIBERSAM), a consortium funded by the Spanish Ministry of Science and Innovation (www.cibersam.es). The CIBERSAM is a research organisation with a legal personality whose mission is to perform monographic research on aspects related to mental health. It is composed of twenty-five research groups belonging to different universities, hospitals, and research centres. Research into the efficacy and safety of drug treatment for psychiatric disorders in children and adolescents is one of its priorities.

Profile of staff members and previous experience

Celso Arango, MD, PhD is a psychiatrist and Associate Professor of Psychiatry at the University of Maryland in Baltimore and the Universidad Complutense in Madrid. Head of the Adolescent Unit of the Department of Psychiatry at HGUGM. He is also Co-ordinator of the Child and Adolescent First-Episode  Psychosis Study (CAFEPS) funded by the Spanish Ministry of Health (including eight centres in Spain) and the Child and Adolescent Neuropsychiatry Network funded by the European College of Neuropsychopharmacology (ECNP). Dr. Arango is the Scientific Director of the Spanish Psychiatric Research Network including 25 centres and more than 400 researchers. He has written more than 200 peer-reviewed articles, 6 books, and more than 30 book chapters. Many of his articles and book chapters have focused on safety of psychiatric medication in paediatric patients (Fraguas et al, J Clin Psychiatry, 2008; Laita, J Child Adolesc Psychopharmacol 2007). He has published relevant papers suggesting the involvement of the histocompatibility system in the ethiology of schizophrenia (Stefanson et al Nature 2009). In addition, his group has showed how patients with a first psychotic episode experience larger losses of gray matter than expected and a correlation of the gray matter loss with the antioxidant status (Reig et al Schiz. Bull 2009, Arango et al in press). Dr. Arango has participated in more than 56 competitively funded research projects being Principal investigator in 41 of them including projects with international funding (Stanley Foundation, NARSAD, etc.) and several clinical drug trials. He is also coordinator of several multicenter projects that assess multi prognostic factors and treatment in early-onset psychosis, participates currently in five EU projects funded by the VII Framework.

Mara Parellada, MD, PhD is a psychiatrist at HGUGM, Assistant Professor of Psychiatry at the Universidad Complutense in Madrid and currently PI for a GxE study funded by the Ministry of Health, conducted in 20 centres throughout Spain, and for the ERANET project ‘From Autism to Schizophrenia‘.

She did her training both in Spain and the UK (Institute of Psychiatry) and has written more than 40 peer-reviewed articles, 1 book and more than 12 book chapters. She is also co-ordinating a multicentre clinical trial funded by the Ministry of Health for the treatment of autistic patients with omega-3 fatty acids.

Dolores Moreno, MD, PhD is an Assistant Professor of Psychiatry at the Universidad Complutense in Madrid and a psychiatrist at HGUGM. She has written more than 35 peer-reviewed articles and more than 8 book chapters. She has conducted research on adolescent schizophrenia and other psychoses, including clinical drug trials.

Carmen Moreno, MD is a psychiatrist at HGUGM. A former research fellow at Columbia University / New York State Psychiatric Institute, focusing on data analysis of US national databases such as the NAMCS (National Ambulatory Medical Care Survey) aimed at studying prescription trends in paediatric populations. She has written more than 10 peer-reviewed articles and 2 book chapters. Currently, she is co-PI of a multicentre independent drug trial in children and adolescents, co-ordinating 4 medical centres and 18 researchers.

Laura Pina-Camacho, MD, is a psychiatrist at HGUGM. Since June 2010, she is as granted pre-doc psychiatrist in the Child and Adolescent Psychiatry Department. She collaborates in all the projects in this department, most of them focused on clinical assessment and treatment of adolescent inpatients with a diagnosis of early onset psychosis, autism spectrum disorders or conduct disorders. She also collaborates in several studies on the effectiveness and safety of pharmacological interventions in children and adolescents.

Petra Sánchez, MD, is a psychiatrist at HGUGM. She has extensive clinical experience in the evaluation and treatment of children and adolescent patients with a diagnosis of early onset psychosis, autism spectrum disorders and conduct disorders. She also collaborates in several studies on the effectiveness and safety of pharmacological interventions in children and adolescents.

Top